Kezdőlap › Krónikus limfocitás leukémia › New York › New York City
Krónikus limfocitás leukémia klinikai vizsgálatok: New York City, NY
18 Krónikus limfocitás leukémia vizsgálat keres résztvevőket New York City és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Toborzás folyamatban1/2. fázis
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Toborzás folyamatbanMegfigyeléses tanulmányEgészséges önkéntesek is jelentkezhetnek
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Toborzás folyamatban3. fázis
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Toborzás folyamatban1/2. fázis
- Research Site, New York
- Research Site, New York
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Toborzás folyamatban3. fázis
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Toborzás folyamatban3. fázis
- Columbia University Medical Center, New York
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Toborzás folyamatban3. fázis
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Toborzás folyamatban3. fázis
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Toborzás folyamatban4. fázis
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Toborzás folyamatban3. fázis
- David H. Koch Center for Cancer Care, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Toborzás folyamatban1/2. fázis
- Research Site, New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Toborzás folyamatban1. fázis
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Toborzás folyamatban2. fázis
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Toborzás folyamatban3. fázis
- Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Toborzás folyamatban2. fázis
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Toborzás folyamatban4. fázis
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Toborzás folyamatban4. fázis
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Toborzás folyamatban1. fázis
- Weill Cornell, New York
Krónikus limfocitás leukémia vizsgálatok más városokban
- Boston, MA31 tanulmány
- Columbus, OH28 tanulmány
- Durham, NC27 tanulmány
- Washington, DC22 tanulmány
- Seattle, WA20 tanulmány
- Rochester, MN18 tanulmány
- Houston, TX17 tanulmány
- Baldwin Park, CA16 tanulmány
- Milwaukee, WI15 tanulmány
- Chicago, IL14 tanulmány
- Cincinnati, OH14 tanulmány
- Nashville, TN13 tanulmány
Egyéb vizsgálatok: New York City
- Mellrák136 tanulmány
- Nem kis sejtes tüdőrák121 tanulmány
- Rák (minden típus)109 tanulmány
- Prosztatarák103 tanulmány
- Áttétes rák93 tanulmány
- Kolorektális rák78 tanulmány
- Petefészekrák69 tanulmány
- Tüdőrák60 tanulmány
- Multiplex mielóma60 tanulmány
- Hasnyálmirigyrák60 tanulmány
- Endometriális rák52 tanulmány
- Akut mieloid leukémia51 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.